Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma

LI Caihe; HU Changchen; CHENG Dongdong; WANG Xiaoyu; GUO Jianzhong

doi:10.14009/j.issn.1672-2124.2022.04.026

您当前的位置：

首页 >

文章列表页 >

Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma

更新时间：2022-10-08

- Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma
- Vol. 22, Issue 4, Pages: 497-503(2022)
- 作者机构：
  
  1. 山西医科大学第五临床医学院
  2. 山西省人民医院神经外科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.04.026
  CLC： R734.2
- Published：2022，
扫描看全文
LI Caihe, HU Changchen, CHENG Dongdong, et al. Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma. [J]. 22(4):497-503(2022)
DOI：

LI Caihe, HU Changchen, CHENG Dongdong, et al. Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma. [J]. 22(4):497-503(2022) DOI： 10.14009/j.issn.1672-2124.2022.04.026.

摘要

非小细胞肺癌(NSCLC)脑转移患者预后差，自然中位生存期短。靶向药物的应用可使NSCLC脑转移患者的生存期显著延长。目前已发现的驱动基因中，表皮生长因子受体(EGFR)基因突变的占比最大，间变性淋巴瘤激酶(ALK)融合基因重排的脑转移发生率最高。针对上述2种基因的靶向药物不断被研发，美国国立癌症综合网络(NCCN)指南也推荐了不同的靶向治疗方案。本文结合NCCN指南，综述靶点为EGFR突变和ALK重排的靶向药物研究现状，聚焦药物颅内效应，旨在为上述2种驱动基因阳性的NSCLC脑转移患者的靶向治疗提供用药参考。

Abstract

Patients with brain metastasis from non-small cell lung carcinoma（NSCLC） have poor prognosis and short natural median survival.The application of targeted drugs can significantly prolong the survival of patients with brain metastases from NSCLC.Among the driving genes found so far

epidermal growth factor receptor（EGFR） mutation accounts for the largest proportion

and anaplastic lymphoma kinase（ALK） rearrangement has the highest incidence of brain metastasis.Targeted drugs for the above two genes are constantly being developed

and the National Comprehensive Cancer Network（NCCN） guidelines recommend different targeted treatment options.This paper reviews the current status of research on drugs targeting EGFR mutation and ALK rearrangement based on NCCN guidelines

focusing on the intracranial effects of drugs

with the aim of providing reference for targeted therapy for patients with brain metastases from the above two driving genes.

关键词

非小细胞肺癌脑转移靶向治疗表皮生长因子受体间变性淋巴瘤激酶

Keywords

Non-small cell lung carcinomaBrain metastasesTargeted therapyEpidermal growth factor receptorAnaplastic lymphoma kinase

references

查看原文

Views

341

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

Expert Consensus on the Chemotherapy Principles of Lung Cancer

Research Status and Hotspots of Treatment for Monoclonal Antibody Drugs

Related Author

CAO Wei

MIN Qiuxia

DONG Lanlan

TU Wenlian

吴永忠

唐颖

吕奇坤

龙建林

Related Institution

Dept.of Pharmacy, the First People’s Hospital of Yunnan/Kunhua Hospital Affiliated to Kunming University of Science and Technology

College of Pharmacy, Dali University

重庆市医学会肿瘤学分会化疗学组

重庆大学附属肿瘤医院肿瘤内科

重庆大学附属肿瘤医院肿瘤放射治疗中心

⁰